Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$CERP .0449 +81% Bullish run confirmed!
$CERP .0449 +81% Bullish run confirmed!
That's what I'm thinking also. AMBS might be holding out for something bigger.
$CERP entering BEAST MODE!
Funny how they seem to always name drop AMBS on every PR.
$CERP is still under a lot of radars! Good for those loading down here!
HUGE BUY! knocked that sucker over!
Vid date prob July 9, 2010 based on one of the ticker headlines "Larry King withdraws divorce..."
Nice collection of AMBS shares you got there! The longs will be rewarded big time eventually...let the traders/flippers do what they do.
$CERP .0248 +115% Charts looking to run!
$CERP .0248 +115% Charts looking to run!
SEC Headquarters
100 F Street, NE
Washington, DC 20549
Please report back with what they say. Thanks!
When I grow up, I want to be like smoke_em! :)
New Diagnostic Approach Targets Parkinson’s Disease
http://theotcinvestor.com/new-diagnostic-approach-targets-parkinsons-disease-1363/
Totally agree smoke_em. AMBS is building a strong vertical pipeline of products to detect and treat PD, Alzheimer, myacardio infarction, TBI.
I've been placing my bets with buys on any pullbacks and building my war chest! :)
GO $AMBS
Goooooop AMBS!!! Woot woot!!!!! KABOOOOOM! WEEEEEE!!!!
It's in Washington DC so prob still going on. Hopefully we'll hear from some members that were suppose to be attending later on tonight or tomorrow.
Great summation. Goes to show AMBS is not a one hit wonder. Many pipeline catalysts to take AMBS to the next level. Everthing will take time ... patience is key.
They are on the landing page of the main site: http://www.blackmoney.com/
"Dr. Commissiong and Gerald Commissiong, President and CEO, are among the 13th annual 50 Most Important African-Americans in Technology. Blackmoney.com executive editor John William Templeton cited them on Federal News Radio in Washington as an example of the most innovative African-American companies Monday, Jan. 14. They will discuss their findings during Innovation & Equity 2013 in April."
"The Company believes the data are positive, even without statistical significance due to small groups of animals in the densitometry and chemistry data, because there are consistent internal results correlating behavior, stereology, densitometry and neurochemistry, most notably at MANF = 10 µg and GDNF = 10 µg. The Company is preparing to initiate IND enabling studies for MANF as a disease-modifying drug candidate for Parkinson’s disease."
Thanks for the article. $AMBS
For those that are concerned with dilution due to cash shortage. The $1.1 million financing received back in Nov 2012 provided "the Company with roughly a year’s worth of funding at our current burn rate giving us the time to diligently market the MANF opportunity to potential partners as well as look at creative financing structures to ensure MANF and NuroPro’s further development. "
http://www.blackmoney.com/49276
Guys, that is an inaccurate statement. Gerald added 50K shares last week...the ~7.5 million amount is the "Amount of Securities Beneficially Owned Following Reported Transaction(s)"
As of 1/14/2013 Gerald owes 7,542,300 shares.
Perhaps this is what he is trying to post ?
http://ih.advfn.com/p.php?pid=nmona&article=55025946
(note: Nov. 2012 PR)
In addition....Dr. Commissiong discovered the protein and has vested many years of sweat and tears in research. If the confirming test results validate the efficacy of MANF, they are not letting it go for pennies on the dollar...they are getting full value; ie hundreds of millions if not billions.
Hold for the gold.
CEO BUYING $AMBS 0.1105 +0.0225 (+25.57%)
http://www.sec.gov/Archives/edgar/data/1424812/000114420413002141/xslF345X03/v331960_4.xml
CEO BUYING $AMBS 0.1105 +0.0225 (+25.57%)
http://www.sec.gov/Archives/edgar/data/1424812/000114420413002141/xslF345X03/v331960_4.xml
Nice call....big buys coming EOD.
1/14/2013 1) CEO Updates Chairman's blog
http://www.thechairmansblog.com/gerald-commissiong/2013-01/onwards-and-upwards-building-value-from-a-solid-foundation.html
2) SEC Form 4. CEO buying shares on 1/11 and 1/14
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9016881
3) AMBS will be at
http://www.blackmoney.com/3973
Keeping America First in Technology: Public Innovation and Supplier Diversity is the theme of the 13th annual Innovation & Equity Symposium honoring the 50 Most Important African-Americans in Technology, convening Jan. 15, 2013 at B. Smith Union Station, 50 Massachusetts Ave. in Washington, D.C.
Company just continues to amaze in Pennyland!!
Not sure if you are asking how I know whether he bought or sold.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9016881
Look @ the column that says "(A) or (D)"
A = Acquired
D = Disposed
CEO is BUYING NOT selling.
It's in black and white and NOBODY can refute this fact!
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9016881
All I know is by next month 1,000,000,000 shares hit the market
Please provide evidence of this?
CEO BLOG (1/14/2013) Onwards and Upwards: Building Value From a Solid Foundation
SOURCE: http://www.thechairmansblog.com/gerald-commissiong/2013-01/onwards-and-upwards-building-value-from-a-solid-foundation.html
The last few weeks have been very exciting for Amarantus. Since our initial Chairman’s Blog post on December 11th, 2012 we have achieved several important corporate milestones to set the stage for growth in 2013, including:
Publicly releasing groundbreaking efficacy data for our protein drug candidate MANF in a neurorestoration animal model of Parkinson’s disease, our lead therapeutic indication;
Acquiring 25 pieces of intellectual property from Power3 Medical Products, Inc. (“Power3”) related to the diagnosis of a number of neurodegenerative diseases and cancers. The transaction also included the buyout of our Parkinson’s disease license with Power3; and
Licensing a Phase 2-ready Alzheimer’s disease diagnostic blood test called LymPro to detect mild to moderate Alzheimer’s disease; a diagnostic category highly sought by Big Pharma
The fundamentals of the Company have continued to progress and this was validated last week when the Company attended two key conferences in San Francisco, where we met with research analysts, fund managers and pharmaceutical executives. This increase in awareness also comes with a significant increase in scrutiny as it relates to the manner in which our data sets are presented and our financing plans. Therefore, I will address some of these key areas here:
The data the Company released last week related to our MANF program in Parkinson’s disease is groundbreaking and first of its kind in the Parkinson’s space. Our Chief Scientific Officer, Dr. John Commissiong, presented the data at the OneMedForum 2013 Healthcare Conference, and showed a significant positive impact in every data category, thus supporting advancing MANF in both Investigational New Drug (“IND”)- enabling studies and human clinical studies. From an academic standpoint, the data produced represents a new ‘positive control’ for this model, heretofore changing the way these experiments are performed in academic labs throughout the world, with MANF likely becoming the new standard. As such, it is important for the experiments to be repeated in academia to get the most efficacious dosing regimen in the model so that new therapies can be compared against the budding new standard, MANF.
While we are constantly evaluating options as it relates to our financial structure, including grants, partnerships, joint ventures, collaborations, and securities offerings, the Company has not made any specific decisions as to its next steps in this regard, despite misleading articles written on certain websites. The Company believes these misleading statements may be intended to dampen market enthusiasm, while enhancing trading strategies for certain trading groups. We are evaluating legal options as it relates to these misleading statements and the Company will continue to work to defend shareholder value. Concurrently with this, we will be taking stronger action against the unauthorized listing of our common stock on the Berlin Stock Exchange, as the Company believes the misleading articles may be related to this listing.
As MANF continues forward in its development, the Company expects to build the most accretive value in the near-term from its diagnostic assets. As previously discussed, the Company is now in an excellent negotiating position with potential partners and investors interested in advancing our diagnostic candidates forward on favorable terms so we can devote the majority of our internal resources to our MANF programs in Parkinson’s disease, Traumatic Brain Injury, Cardiac Ischemia and the evaluation of certain orphan indications. We will update the marketplace regarding our diagnostic assets and plans for their continued development in the near future.
In closing, the future has never looked brighter for Amarantus. We have unambiguous data supporting MANF’s further development in our lead Parkinson’s disease indication, we now have rights to seven diagnostic blood tests in significant markets, and our MANF asset continues to make progress in secondary indications. We are looking forward to an exciting 2013 for the Company and its shareholders.
I thank you for taking the time to read this letter and looking forward to communicating with you in the future.
Sincerely,
Gerald E. Commissiong
President & Chief Executive Officer
Agreed as well. $AMBS is as legit as it gets in Pennyland. If the fundamentals continue to progress and with the Advisory board guidance/connections....we won't be here for much longer.
Next leg coming very soon! :)
1)AMBS went from 0.004 to 0.02
2)AMBS went from 0.0048 to 0.087
3)AMBS went from 0.017 to 0.195
4)Next AMBS from 0.069 to....????Enjoy the run !
Long and still here....only get 1 post so I wanted to make sure I make the best of it. Oh snap, damn it!
GO $AMBS!
There are arrows on the bottom right on the audio player. You have to manually click to follow along with Gerald's presentation. Should be @ slide 14 now.
I am pretty certain Dr. R reached out to his contacts prior and they were watching the presentation.
I couldn't have asked for anything better as far as the results go (although I don't know what it all means, from what I was able to gather from the charts...MANF is indeed superior to GNDF). The next few weeks will be the beginning of something very exciting/big!
Pharma Deals North of $10 Billion Seen Returning in 2013
Looks like this might help $AMBS. :)
(Article Excerpt):
There have been 676 takeovers of biotechnology and pharmaceutical companies in the last three years, according to data compiled by Bloomberg. The average disclosed deal size was $328.7 million, and the average premium, 38 percent. The largest acquisition was Sanofi’s takeover of Genzyme Corp. in 2011 for $20.1 billion. Only two deals topped $10 billion; the other was Foster City, California-based Gilead’s purchase of Pharmasset.
AbbVie Inc., the drug unit that split from parent Abbott on Jan. 1, is seeking treatments for unmet medical needs, such as Parkinson’s and endometriosis, to increase sales in 2015, Chief Financial Officer William Chase said last week.
Bristol-Myers is looking to buy a new type of Alzheimer’s disease drug to restock its pipeline after the failure of its experimental compound avagacestat, said Mark Day, who heads the company’s neuroscience business development.
Merck will consider “targeted deals” while seeking to avoid a big merger, Chief Executive Officer Kenneth Frazier said last week at a Goldman Sachs Group Inc. (GS) conference. Frazier said further industry consolidation is likely, considering pricing pressures, the costs and risks of clinical studies, and a “certain redundancy of infrastructure” in the industry.
"With cost restructuring and portfolio realignments largely behind us, pharma is now more ready to make bigger moves again," Gosebruch said. “They are going to be back in a more aggressive way.”
http://www.bloomberg.com/news/2013-01-07/pharma-deals-north-of-10-billion-seen-returning-in-2013.html
Nice post! I will use my restricted 1 post/day to repost your post! :^)
AVOID THE NOISE!! WE ARE DOING FINE CHARTS/FUNDAMENTALS!
NOTHING HAS CHANGED!
1/3/13 Update: Fellow AMBS longs,
Over the past 8 trading hours we’ve seen a very healthy pull back forming support in the .14s. All longs still in the hunt are sitting on nice profits, and now we have shaken out a lot of flippers and weak hands in exchange for new investors. A retracement of this nature was inevitable and is the other side of this AMBS beast. I picked up a couple more shares in the low .15s and high .14s today, and have been watching the intraday closely all day. I am not worried at all about our long position and am still equally as optimistic as I have been this whole ride. Our data presentation after market close on January 8th will provide a MAJOR catalyst that is fundamentally natural and organic as opposed to bogus reports like the buyins.net squeeze trigger articles. Not only are we expecting data that shows ~30% better results than a drug, GDNF, valued at $250 million preclinical, but Dr. Rubinfield will be presenting immediately after on the commercialization potential of MANF. This conference is not one of those assemblies where a bunch of science dorks come together to show off their projects, its an investors conference. We have one of the most reputable scientists of the past century ready to talk about some HUGE, multi billion dollar markets MANF is preparing to run for. Not only will this potentially bring in much needed funding for AMBS, it will bring in a lot of deep pocket investors who will be joining us longs in the ride of a lifetime. Don’t lose sleep over the day-to-day movement of this stock. All your focus should be on the true value of MANF and AMBS, and the data coming out as positive as we expect. This is all just white noise in the grand scheme of things.
$2 coming sooner rather than later
~Lewsogge
************
Know what you own AMBS DD:
https://docs.google.com/document/d/1V10erwVdBvy6Um35Ay8XV0wV3TAPr6oME2fJG_jFvl4/edit